These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24257372)

  • 1. PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST.
    Hansson EK; Amantea MA; Westwood P; Milligan PA; Houk BE; French J; Karlsson MO; Friberg LE
    CPT Pharmacometrics Syst Pharmacol; 2013 Nov; 2(11):e84. PubMed ID: 24257372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST.
    Hansson EK; Ma G; Amantea MA; French J; Milligan PA; Friberg LE; Karlsson MO
    CPT Pharmacometrics Syst Pharmacol; 2013 Dec; 2(12):e85. PubMed ID: 24304978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
    Harmon CS; DePrimo SE; Raymond E; Cheng AL; Boucher E; Douillard JY; Lim HY; Kim JS; Lechuga MJ; Lanzalone S; Lin X; Faivre S
    J Transl Med; 2011 Jul; 9():120. PubMed ID: 21787417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
    Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
    J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib.
    Keyvanjah K; DePrimo SE; Harmon CS; Huang X; Kern KA; Carley W
    J Transl Med; 2012 Aug; 10():165. PubMed ID: 22897944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-based Dose Individualization of Sunitinib in Gastrointestinal Stromal Tumors.
    Centanni M; Krishnan SM; Friberg LE
    Clin Cancer Res; 2020 Sep; 26(17):4590-4598. PubMed ID: 32522885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.
    Deprimo SE; Huang X; Blackstein ME; Garrett CR; Harmon CS; Schöffski P; Shah MH; Verweij J; Baum CM; Demetri GD
    Clin Cancer Res; 2009 Sep; 15(18):5869-77. PubMed ID: 19737953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
    Norden-Zfoni A; Desai J; Manola J; Beaudry P; Force J; Maki R; Folkman J; Bello C; Baum C; DePrimo SE; Shalinsky DR; Demetri GD; Heymach JV
    Clin Cancer Res; 2007 May; 13(9):2643-50. PubMed ID: 17473195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours.
    Zurita AJ; Khajavi M; Wu HK; Tye L; Huang X; Kulke MH; Lenz HJ; Meropol NJ; Carley W; DePrimo SE; Lin E; Wang X; Harmon CS; Heymach JV
    Br J Cancer; 2015 Mar; 112(7):1199-205. PubMed ID: 25756398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
    Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
    Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors.
    Centanni M; Friberg LE
    Front Pharmacol; 2020; 11():316. PubMed ID: 32226388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer.
    Perroud HA; Rico MJ; Alasino CM; Pezzotto SM; Rozados VR; Scharovsky OG
    Indian J Cancer; 2013; 50(2):115-21. PubMed ID: 23979202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers.
    Lindauer A; Di Gion P; Kanefendt F; Tomalik-Scharte D; Kinzig M; Rodamer M; Dodos F; Sörgel F; Fuhr U; Jaehde U
    Clin Pharmacol Ther; 2010 May; 87(5):601-8. PubMed ID: 20376000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker.
    Kanefendt F; Lindauer A; Mross K; Fuhr U; Jaehde U
    J Pharm Biomed Anal; 2012 Nov; 70():485-91. PubMed ID: 22819208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.
    Lamszus K; Ulbricht U; Matschke J; Brockmann MA; Fillbrandt R; Westphal M
    Clin Cancer Res; 2003 Apr; 9(4):1399-405. PubMed ID: 12684411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients.
    Yuan J; Guo Q; Qureshi AR; Anderstam B; Eriksson M; Heimbürger O; Bárány P; Stenvinkel P; Lindholm B
    Nephrol Dial Transplant; 2013 Sep; 28(9):2356-63. PubMed ID: 23828162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6.
    Aoyagi Y; Iinuma H; Horiuchi A; Shimada R; Watanabe T
    Oncol Lett; 2010 Mar; 1(2):253-259. PubMed ID: 22966290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium.
    Kaza E; Ablasser K; Poutias D; Griffiths ER; Saad FA; Hofstaetter JG; del Nido PJ; Friehs I
    Cardiovasc Res; 2011 Feb; 89(2):410-8. PubMed ID: 20935166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer.
    Thielemann A; Baszczuk A; Kopczyński Z; Kopczyński P; Grodecka-Gazdecka S
    Ann Agric Environ Med; 2013; 20(2):293-7. PubMed ID: 23772579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.